Non-Hodgkin Lymphoma, Multiple Myeloma

Non-Hodgkin Lymphoma, Multiple Myeloma

About GDA-201

GDA-201 is an innate natural killer (NK) cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. When combined with targeted antibodies, GDA-201 has shown enhanced antibody-dependent cellular toxicity, or ADCC.

Clinical Trial Information

GDA-201 is being evaluated in a Phase 1 clinical study in patients with refractory non-Hodgkin lymphoma and multiple myeloma.

For more information about the study, please visit

Send us a message